At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 484 enrolled
Drug / intervention
RVT-101 35 mg +2 moredrug
Likely dose
RVT-101 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
In Brief
A Phase 2 clinical trial evaluating RVT-101 35 mg, RVT-101 70 mg, and 1 other intervention for Dementia With Lewy Bodies. Completed, enrolled 484 participants across 65 sites in 7 countries.
Detailed Summary
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia With Lewy Bodies
CountriesCanada, France, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedFeb 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedFeb 1, 2016
Enrollment StartJan 1, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.4 years ago
Interventions
RVT-101 35 mgdrug
once daily, oral, 35-mg tablets
RVT-101 70 mgdrug
once daily, oral, 35-mg tablets
Placebodrug
once daily, oral, matching tablets